FDA Announces Final Guidance for Industry on Formal Meetings with ANDA Applicants for Complex Products

Summary

The Food and Drug Administration (FDA) has released a final guidance document outlining enhanced pathways for discussions between FDA and applicants preparing to submit abbreviated new drug applications (ANDAs) for complex products, in accordance with the Generic Drug User Fee Amendments (GDUFA II)